Effect of Immunosuppression in IgA nephropathy

Yonsei University Health System, Severance Hospital0 个研究点目标入组 172 人开始时间: 待定最近更新: 2019年3月11日

试验速览

暂无简介。

•1) Biopsy-proven IgA nephropathy
•2) Urinary protein excretion above the target of 1.0 g per day despite the dose of renin–angiotensin system blocker is
•increased to the maximum approved daily dose
•3) Blood pressure lower than 130/80 mmHg after administration of renin–angiotensin system blocker,
•and other kinds of anti-hypertensive medications if needed
•4) eGFR =30 ml per minute per 1.73 m2
•5) Age =19-years old

•1)Candidate for immunosuppressive therapy
•?Minimal change disease with IgA nephropathy
•?Crescents= 25% in biopsy findings
•2)Contraindication for immunosuppressive therapy
•?Active pulmonary tuberculosis
•?Diagnosed with cancer in the last 5 years
•?Planning for pregnancy or breastfeeding
•?Acute hepatitis, chronic hepatitis, liver cirrhosis, HIV infection
•?Gastrointestinal bleeding within 2 weeks
•?Need for maintenance of immunosuppressive therapy for other reasons (e.g., transplant patients, inflammatory bowel diseases that require steroid treatment)
•3)Recent immunosuppressive therapy within the past year
•Patients with less than 10mg of steroid can can be enrolled after 3 months of discontinuation
•4)Uncontrolled hypertension (BP=160/100 mmHg)
•5)Diabetes mellitus (fasting blood glucose=126 mg/dL, or HbA1c=6.5%, or the use of antidiabetic medications)
•6)Age<19-years old
•7)Secondary IgA nephropathy: lupus nephritis, liver cirrhosis, Henoch-Sholein purpura
•8)Patients who participated in other clinical trials within the last 3 months

发起方